Two Court Decisions Shape Future of Pharmaceutical Trade Secret Litigation

A U.S. District Court in San Francisco has dismissed a pharmaceutical company's trade secrets lawsuit against former employees and their new employer, while a separate Federal Circuit ruling provides new guidance for defendants seeking appellate review. In the first case, the court granted a motion to dismiss in its entirety, finding the plaintiff failed to plausibly allege misappropriation of trade secrets. The second decision clarifies that trade secret defendants may have a stronger path to appeal before the Federal Circuit, even when patent claims have been dismissed.

The dismissed case, PTC Therapeutics, Inc. v. AcureX Biosciences Corp., involved allegations that two former doctors from BioElectron used confidential information to develop a new drug for treating neurodegenerative diseases at AcureX. PTC Therapeutics, which had purchased assets from BioElectron including the drug Vatiquinone and a chemical library, sued the doctors and AcureX for misappropriation of trade secrets under federal and California law. The court held that the complaint did not plausibly allege an act of misappropriation. The ruling stated that the mere allegation that the doctors worked on related projects at two different employers, without more, was not sufficient to show they misappropriated materials. Similarly, similarity between drug products without more was not sufficient to show misappropriation. The court dismissed all claims, including breach of contract and unfair competition, with leave to amend.

This dismissal illustrates a hurdle for trade secret plaintiffs, particularly those relying on theories of inevitable disclosure. The court rejected the idea that misappropriation was inevitable just because the doctors worked on similar subject matter for the new employer.

In a separate but related legal development, the Federal Circuit's recent decision in Insulet Corp. v. EOFlow Co. offers trade secret defendants a clearer path to federal appellate jurisdiction. Insulet, a medical-device manufacturer, had initially asserted both trade secret and patent infringement claims but voluntarily dismissed the patent claims without prejudice. Despite this dismissal, the Federal Circuit concluded it retained jurisdiction over the remaining trade secret claims.

The key to the ruling was the court's interpretation of a 2004 precedent, Chamberlain Group Inc. v. Skylink Technologies Inc. Under that framework, a dismissal can be treated as final for jurisdictional purposes if the claim can no longer be refiled, altering the parties' legal positions. In the Insulet case, the voluntary dismissal of patent claims functioned as a dismissal with prejudice because refiling would be barred by the six-year time limitation in 35 U.S. Code § 286.

This reasoning may have broader implications. Legal experts suggest the logic could extend to cases with compulsory patent counterclaims that were dismissed, even voluntarily. A defendant who asserts a compulsory patent infringement counterclaim but later dismisses it could argue that Federal Circuit jurisdiction survives, as the dismissal carries legal consequences analogous to those in the Insulet decision. This could provide trade secret defendants in non-patent intellectual property disputes a new avenue for Federal Circuit review, which is significant in cases with potential for high damages awards.

Both decisions underscore evolving dynamics in pharmaceutical and intellectual property litigation. The dismissal of the PTC Therapeutics case demonstrates the high bar for proving trade secret misappropriation when employees change employers within the same industry. Meanwhile, the Federal Circuit's ruling in Insulet reshapes procedural strategies for defendants seeking to litigate trade secret disputes at the appellate level.